Quelling of Excitotoxicity in Acute Stroke With Ketamine "QUEST-KETA"

Not yet recruiting

Phase 2/3 Results N/A

Summary of Purpose

The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 2 February 2018.

1 Apr 2018 14 Jul 2017 31 Mar 2019 31 Dec 2019 1 Feb 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

Not available